Comparison of alteplase infusion with all other thrombolytic regimens for the treatment of pulmonary embolism(PE)
| Study or subcategory | Alteplase infusion n/N | Other regimens n/N | Weight % | Fixed RR (95% CI) |
| All-cause mortality# | ||||
| Goldhaber et al. 8 | 2/22 | 2/23 | 22.16 | 1.05 (0.16–6.79) |
| Goldhaber et al. 16 | 2/42 | 1/45 | 10.94 | 2.14 (0.20–22.77) |
| Meyer et al. 14 | 3/34 | 1/29 | 12.23 | 2.56 (0.28–23.29) |
| Goldhaber et al. 20 | 1/27 | 5/60 | 35.16 | 0.44 (0.05–3.62) |
| Sors et al. 19 | 0/17 | 0/36 | NE | |
| Meneveau et al. 21 | 1/25 | 1/25 | 11.33 | 1.00 (0.07–15.12) |
| Meneveau et al. 22 | 0/23 | 0/43 | NE | |
| Tebbe et al. 24 | 2/13 | 1/23 | 8.18 | 3.54 (0.35–35.37) |
| Subtotalƒ | 203 | 284 | 100 | 1.34 (0.57–3.14) |
| Deaths due to initial PE¶ | ||||
| Goldhaber et al. 8 | 0/22 | 1/23 | 44.68 | 0.35 (0.01–8.11) |
| Goldhaber et al. 16 | 0/42 | 1/45 | 44.11 | 0.36 (0.01–8.52) |
| Meyer et al. 14 | 0/34 | 0/29 | NE | |
| Goldhaber et al. 20 | 0/27 | 0/60 | NE | |
| Sors et al. 19 | 0/17 | 0/36 | NE | |
| Meneveau et al. 21 | 0/25 | 0/25 | NE | |
| Meneveau et al. 22 | 0/23 | 0/43 | NE | |
| Tebbe et al. 24 | 1/13 | 0/23 | 11.21 | 5.14 (0.22–117.87) |
| Subtotalƒ | 203 | 284 | 100 | 0.89 (0.20–4.02) |
| Deaths due to recurrent PE+ | ||||
| Goldhaber et al. 8 | 0/22 | 1/23 | 27.35 | 0.35 (0.01–8.11) |
| Goldhaber et al. 16 | 0/42 | 0/45 | NE | |
| Meyer et al. 14 | 1/34 | 0/29 | 10.03 | 2.57 (0.11–60.81) |
| Goldhaber et al. 20 | 1/27 | 3/60 | 34.68 | 0.74 (0.08–6.80) |
| Sors et al. 19 | 0/17 | 0/36 | NE | |
| Meneveau et al. 21 | 0/25 | 1/25 | 27.94 | 0.33 (0.01–7.81) |
| Meneveau et al. 22 | 0/23 | 0/43 | NE | |
| Tebbe et al. 24 | 0/13 | 0/23 | NE | |
| Subtotalƒ | 203 | 284 | 100 | 0.70 (0.19–2.62) |
| Recurrent PE§ | ||||
| Goldhaber et al. 16 | 0/42 | 3/45 | 27.05 | 0.15 (0.01–2.87) |
| Meyer et al. 14 | 2/34 | 2/29 | 17.27 | 0.85 (0.13–5.68) |
| Goldhaber et al. 20 | 2/27 | 4/60 | 19.86 | 1.11 (0.22–5.70) |
| Sors et al. 19 | 1/17 | 2/36 | 10.26 | 1.06 (0.10–10.88) |
| Meneveau et al. 21 | 0/25 | 2/25 | 19.99 | 0.20 (0.01–3.97) |
| Meneveau et al. 22 | 2/23 | 1/43 | 5.57 | 3.74 (0.36–39.07) |
| Subtotalƒ | 168 | 238 | 100 | 0.77 (0.34–1.72) |
RR: relative risk; CI: confidence interval; NE: not estimable. #: total events, 11 (alteplase infusion), 11 (other regimens); test for heterogeneity, Chi-squared = 2.34, df = 5 (p = 0.80), l2 = 0%; test for overall effect, z = 0.67, p = 0.50. ¶: total events, 1 (alteplase infusion), 2 (other regimens); test for heterogeneity, Chi-squared = 1.87, df = 2 (p = 0.39), l2 = 0%; test for overall effect, z = 0.15, p = 0.88. +: total events, 2 (alteplase infusion), 5 (other regimens); test for heterogeneity, Chi-squared = 1.05, df = 3 (p = 0.79), l2 = 0%; test for overall effect, z = 0.53, p = 0.60. §: total events, 7 (alteplase infusion), 14 (other regimens); test for heterogeneity, Chi-squared = 3.97, df = 5 (p = 0.55), l2 = 0%; test for overall effect, z = 0.65, p = 0.52. ƒ: 95% CI.